Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Accured Expenses (2016 - 2025)

Guided Therapeutics' Change in Accured Expenses history spans 15 years, with the latest figure at $204000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 209.09% year-over-year to $204000.0; the TTM value through Sep 2025 reached $687000.0, up 22.24%, while the annual FY2024 figure was $545000.0, 1167.44% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $204000.0 at Guided Therapeutics, down from $221000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $571000.0 in Q4 2021 and bottomed at -$450000.0 in Q3 2021.
  • The 5-year median for Change in Accured Expenses is $66000.0 (2024), against an average of $72473.7.
  • The largest annual shift saw Change in Accured Expenses plummeted 454.33% in 2021 before it skyrocketed 2009.52% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $571000.0 in 2021, then tumbled by 77.41% to $129000.0 in 2022, then skyrocketed by 34.11% to $173000.0 in 2023, then fell by 9.83% to $156000.0 in 2024, then surged by 30.77% to $204000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Change in Accured Expenses are $204000.0 (Q3 2025), $221000.0 (Q2 2025), and $106000.0 (Q1 2025).